Abstract: Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane.

Abstract: The present invention provides compositions that may be an aqueous insecticide containing at least one surfactant, such as for instance, sodium lauryl sulfate, at least one preservative, such as for instance, a potassium salt or sodium chloride, a nutrient source, such as for instance a yeast, an organic acid capable of lowering the pH of the aqueous insecticide, such as for instance citric acid, a fragrance, such as for instance geranium oil, and water. The aqueous insecticide may be designed to more efficiently kill and thereby control populations of species of Cimex, such as, for instance, Cimex lectularius.

Abstract: The invention relates to a composition, particularly in the form of liquid to be used externally as a rinsing contact lenses, containing nanocrystalline photocatalyst active in visible light, and optionally hydrogen peroxide.

Abstract: Different components of natural oils are separated by forming solid complexes of components of the natural oil with a solvent, and then separating the solid complexes from the remaining liquids. The natural oil is cooled in the presence of a solvent, and at least one component of the oil forms the solid complex with the solvent. This solid complex is separated from the remaining liquid portion of the oil solution, which also contains the solvent. Additional options concentration steps can further concentrate the components left in the liquid phase.

Abstract: Disclosed herein are compositions that can rapidly evolve oxygen and/or activated oxygen generally including an oxidizing agent (e.g., a peroxide) and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B, Eosin Y, or Erythrosine B). Methods of employing these compositions to whiten teeth, and methods of making these compositions and kits that include some or part of the composition ingredients, are also described.

Abstract: A solubilizing composition containing (A) at least one oily component selected from esters of oleic acid with alcohols having 1 to 3 carbon atoms and triglycerides of fatty acids having 6 to 12 carbon atoms, (B) a polyoxyethylenesorbitan fatty acid ester, (C) a polyhydric alcohol which is liquid between 15° C. and 25° C., and (D) one or more acidic phospholipids where the fatty acid constituting an acyl group thereof is selected from saturated fatty acids having 6 to 14 carbon atoms and unsaturated fatty acids having 16 to 18 carbon atoms, which contains 20 to 40% by weight of the component (A), 30 to 45% by weight of the component (B), 15 to 40% by weight of the component (C), and 0.5 to 4% by weight of the component (D), based on 100% by weight of a total amount of the components (A) to (D).

Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.

Abstract: Cosmetic or dermatological emulsions having a content of one or more acyl arginates of formula (I), where R and R2 independently of each other can be H and C5-22-alkyl, in particular formula (II) or formula (III), wherein said acyl arginates can also be present as salts, for example hydrochlorides.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: The disclosure relates to metal organic frameworks or isoreticular metal organic frameworks, methods of production thereof, and methods of use thereof.

Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.

Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Abstract: A method and composition for administering a therapeutic composition to a lesion comprising about 20% to about 50% ethanol and other novel therapeutic agents.

Abstract: A compound of formula (I) wherein R1 and R2 are independently selected from hydrogen, methyl, ethyl, propyl and isopropyl; or R1 and R2 together form a saturated or monounsaturated 5- or 6-membered hydrocarbon ring, as represented by the arcuate dotted line; R3 is selected from methyl and ethyl; R4 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, cyclobutyl and cyclopentyl; R5 is selected from hydrogen and methyl, and the dotted line between positions 3? and 4? represents an optional double bond. The compounds have a musk odour and are useful in fine and functional fragrances.

Abstract: The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and protection from hair loss.

Abstract: Cosmetic or dermatological preparations show improved sensory properties and sufficient microbiological stability due to the addition of benzethonium chloride, methylisothiazolinone, piroctone olamine and/or lauroyl ethyl arginate, the cosmetic or dermatological preparations not comprising any other preservatives, and are especially free of parabens and/or phenoxyethanol.

Abstract: The present invention relates to the use of a compound of general formula: wherein X is a CiO-24 carbon chain with “n” unsaturations wherein “n” is an integer from zero to 3 for the preparation of a cosmetic composition and a pharmaceutical composition to increase the skin permeation and retention of active ingredients. The present invention is suitable for cosmetic and pharmaceutical products the activity of which is enhanced with increased permeation and retention of active ingredients in the skin as a treatment for cellulite and fat accumulation, acne treatment, skin whitening amongst others.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: This disclosure relates to a method and a system of producing nanoparticles and nanoparticle matrices of thermolabile, biocompatible matrix materials, like lipids and biopolymers with controlled properties. A prototype pulse-heat aerosol system is described for single-step production of free, thermolabile nanoparticles with sufficient control over size, morphology and crystallinity with controlled-release properties, for possible therapeutic, cosmetic or diagnostic use. Nanoparticles of the range 50 to 500 nm are obtained and are found suitable for controlled drugs delivery.

Abstract: The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T11 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging.

Abstract: A solid dosage form suitable for forming a tablet for the containment and delivery of medicament is provided wherein the matrix forming material is a pressure sensitive adhesive, present in the amount from about 0.1 to about 40 weight %, based on the total weight of the composition. The dosage form is comprised of the medicament and a water-insoluble polymer silicone pressure sensitive adhesive and allows release of the medicament in a controlled fashion depending on simple parameters such as weight percent of the polymer silicone adhesive. A sustained release dosage form is provided for delivery of medicament wherein the release rate of medicament does not depend on the dissolution medium of the pH. Another aspect of invention is formation of solid tablets of poorly compressible material and the method for making the solid composition. The dosage form for this invention s particularly suitable for oral dosage forms.

Abstract: The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same. Polymers formed from the functionalized amino acids are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: An emulsifiable concentrate (EC) is provided. The EC includes an active component, a solvent component, and an emulsifier component. The active component is present in an amount of from 20 to 90 parts by weight per 100 parts by weight of the emulsifiable concentrate. The solvent component includes 1,2-cyclohexanedicarboxylic acid diisononyl ester. The emulsifier component is present in an amount of from 5 to 15 parts by weight per 100 parts by weight of the emulsifiable concentrate and includes an anionic surfactant, a non-ionic surfactant, and a surfactant including at least one ethylene oxide block. Moreover, the active component is dissolved in the solvent component.

Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.

Abstract: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes a nonionic primary surfactant comprising an ethoxylated sorbitol oleate, a nonionic secondary surfactant, and water. The nonionic secondary surfactant is selected from the group consisting of linear ethoxylated secondary alcohols, polyoxyethylene ethers, ethoxylated sorbitan monolaurates, ethoxylated fatty acid amides and ethoxylated fatty acids that contain about 7 moles to about 26 moles of ethylene oxide and comprise from about 20 to about 36 weight percent of said composition. The water is in a sufficient amount so that the nonionic primary and secondary surfactants together with the water form a gel.

Abstract: A new emulsified cosmetic composition involving ?-gel, and the viscosity of the emulsified composition does not decrease over time even when salts are not added. The composition contains (A)-(E) ingredients, where (A) ingredient is a higher aliphatic alcohol, (B) ingredient is an anionic surfactant, (C) ingredient is a cationic surfactant, (D) ingredient is water, (E) ingredient is an oil component. The blend ratio of (B) ingredient is 1-15 times of the blend ratio of (C) ingredient in terms of the mole ratio.

Abstract: The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin.

Abstract: Described herein are compositions comprising an acidifier intermixed with an emulsifier and a co-surfactant that form stable microemulsions in water. Also described are methods of dispersing a compound in an aqueous solution using the compositions of the present invention.

Abstract: The present invention relates to a double component type deodorant which comprises a first deodorant component A containing a liquid mixture containing a polyphenol and an acid agent and a second deodorant component B containing an alkali agent and an aqueous solvent. These deodorant components A and B may be separately stored in different storage parts. According to the invention, mixed type malodors in which at least two or more kinds of a sulfur-containing compound, aldehydes, lower fatty acids, amines, and the like are mixed can be efficiently deodorized.

Abstract: The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to anemulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C1-C6) alkyl esters of the aforementioned acids, or mixtures thereof, and wherein the oil phase comprises at least one membrane-forming substance forming a lamellar arranged membrane in the emulsion.

Abstract: The present invention is directed to compositions and methods of preparation of phospholipid depots that are injectable through a fine needle.

Abstract: A pharmaceutical composition intended to be applied to a perforated nail is described. In particular, a composition is descirbed that includes an antifungal agent that is in the form of an acid salt, advantageously a hydrochloride; and a solvent system; and advantageously a cationic or positively charged amphoteric surfactant. The described composition can have a viscosity of less than 500 cPs.

Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.

Abstract: The present invention relates to foamable oil-in-water emulsions containing: A) one or more emulsifiers, at least one of which is a non-ionic emulsifier, B) one or more cotensides, C) one or more oils, D) optionally, one or more polar solubilizers, E) optionally, auxiliary and additive substances, F) one or more surfactants, G) water, H) optionally, water-soluble substances, provided that the water content of the emulsion is ?70% by weight and the concentration of surfactant(s) F) is from 0.01 to less than 10% by weight, each based on the entire emulsion. The invention further relates to a method for producing the oil-water emulsions according to the invention, to foams obtained from these oil-water emulsions, to a method for producing the foams, and to the application of the oil-water emulsions according to the invention and to the foams produced therefrom.

Abstract: The invention relates to a silicone-free skin protection composition, in particular a composition to protect against cold, containing the components a.) at least one oil with a pour point in accordance with DIN ISO 30 16 of ??10° C., b.) at least one polyol c.) at least one emulsifier d.) optionally at least one wax, where the viscosity difference in the temperature interval from +4° C. to +50° C. of highest and lowest viscosity of the skin protection composition has a value in the range from 0 to ?20 000 mPas.

Abstract: A compressed core for a pharmaceutical dosage form comprising a mixture of (a) at least one pharmaceutically acceptable organic acid, and (b) at least one pharmaceutically acceptable excipient is described. Such compressed core is useful for the preparation of pharmaceutical compositions containing a drug in which dissolution of the drug is favored in acidic environments. Also described are pharmaceutical compositions comprising such compressed core.

Abstract: The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.

Abstract: The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

Abstract: Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least multivalent metal compound, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive strength in both wet and dry environments which exhibit bond strength upon curing with the possible usage as bone cement for bone filler applications.

Abstract: Provided are an emulsion comprising graphene oxide, a first fluid and a second fluid, and a drug delivery system comprising the emulsion. This emulsion is based on the discovery that graphene oxide is an amphiphile with hydrophilic edges and a more hydrophobic basal plane, and thus graphene oxide can act as a surfactant. Since the degree of ionization of the edge —COOH groups of the graphene oxide is affected by pH, the amphiphilicity of graphene oxide can be adjusted based on pH. Therefore, a method of separating a first liquid from a second liquid by providing an emulsion comprising graphene oxide, the first liquid and the second liquid is also provided. It was also discovered that graphene oxide can act as a molecular dispersing agent to process insoluble materials. Based on this discovery, a composition comprising graphene oxide, a solvent and an insoluble solid is provided.

Abstract: Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR109 ligands include, but are not limited to butyrate, ?-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2?-deoxytidine, 1-?-D-arabinfarnosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR109 ligand serum blood level of about 1 to about 1000 ?M. The compositions are useful for the treatment of one or more symptoms of cancer.

Abstract: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.

Abstract: The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.

Abstract: A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 10-50% of Pracaxi oil, 15-40% of Patauá oil, 10-30% of Inaja oil, and 10-30% of one of more emollients.

Abstract: A variety of betaine esters, including dial kylaminoalkyl cocoate betaines. These betaines were advantageously prepared in high yield and purity by a three-step chemoenzymatic process. These betaine esters have excellent surfactant properties.